A phase I-II open-label trial of ispinesib on an alternate dosing schedule in chemotherapy-naive patients with locally advanced or metastatic breast cancer (MBC)
JOURNAL OF CLINICAL ONCOLOGY (2008)
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 26, Issue 15, Pages -Publisher
AMER SOC CLINICAL ONCOLOGY
Keywords
Categories
Ask authors/readers for more resources
Authors
I am an author on this paper
Reviews
Recommended
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
CURRENT ONCOLOGY (2022)
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience
Mark G. Faber, Chong Wang, Sruthi Kommi Reddy, Alison Meagher, Amy Early, Hongbin Chen, Grace K. Dy
LUNG CANCER (2022)
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients withEGFRmutation-positive locally advanced/metastatic non-small-cell lung cancer
Benjamin C. Creelan, Tammie C. Yeh, Sang-We Kim, Naoyuki Nogami, Dong-Wan Kim, Laura Q. M. Chow, Shintaro Kanda, Rosemary Taylor, Weifeng Tang, Mei Tang, Helen K. Angell, Martine P. Roudier, Marcelo Marotti, Don L. Gibbons
BRITISH JOURNAL OF CANCER (2021)
Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)
Anne L. Loeser, Lucy Gao, Aditya Bardia, Mark E. Burkard, Kevin M. Kalinsky, Jeffrey Peppercorn, Hope S. Rugo, Martha Carlson, Janice Cowden, Lesley Glenn, Julia Maues, Sheila McGlown, Andy Ni, Natalia Padron, Maryam Lustberg
BREAST CANCER RESEARCH AND TREATMENT (2022)
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer
Martin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, Niels Reinmuth, Martin Sebastian, Monika Serke, Cornelius Florian Waller, Michael Thomas, Jochen Eggert, Gerald Schmid-Bindert, Mathias Hoiczyk, Daniel Christian Christoph, Martin Kimmich, Burkhard Deuss, Stephanie Seifert, Swantje Held, Martin Schuler, Thomas Herold, Frank Breitenbuecher, Wilfried Ernst Erich Eberhardt
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Jianming Ying, Weiqing Han, Changlu Hu, Yun Ling, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Aiping Zhou, Jun Guo
CLINICAL CANCER RESEARCH (2021)
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
Lucie Meynard, Derek Dinart, Blandine Delaunay, Aude Flechon, Carolina Saldana, Felix Lefort, Gwenaelle Gravis, Antoine Thiery-Vuillemin, Mathilde Cancel, Elodie Coquan, Sylvain Ladoire, Denis Maillet, Frederic Rolland, Elouen Boughalem, Sophie Martin, Mathieu Laramas, Laurence Crouzet, Baptiste Abbar, Sabrina Falkowski, Damien Pouessel, Guilhem Roubaud
EUROPEAN JOURNAL OF CANCER (2022)
Treatment of Locally Advanced/Metastatic Colorectal Cancer
Alan P. Venook, Christopher G. Willett
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
Jemmy Zhao, Susann Stephan-Falkenau, Markus Schuler, Boerge Arndt
CANCERS (2023)
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma
Mrinal M. Gounder, Priscilla Merriam, Ravin Ratan, Shreyaskumar R. Patel, Rashmi Chugh, Victor M. Villalobos, Mark Thornton, Brian A. Van Tine, Amr H. Abdelhamid, Jennifer Whalen, Jay Yang, Anand Rajarethinam, Mei Sheng Duh, Priyanka J. Bobbili, Lynn Huynh, Todor Totev, Angela K. Lax, Shefali Agarwal, George D. Demetri
CANCER (2021)
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Marten, Jin-Hyoung Kang
BMC CANCER (2021)
A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naive prostate cancer
Seonggyu Byeon, Hongsik Kim, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Soon Il Lee, Se Hoon Park
BMC CANCER (2021)
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
Steve Nicholson, Holly Tovey, Tony Elliott, Stephanie M. Burnett, Clare Cruickshank, Amit Bahl, Peter Kirkbride, Anita V. Mitra, Alastair H. Thomson, Naveen Vasudev, Balaji Venugopal, Rachel Slade, Lucy Tregellas, Bruno Morgan, Alison Hassall, Emma Hall, Lisa M. Pickering
BRITISH JOURNAL OF CANCER (2022)
Comparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer
Sergio Martinez-Recio, Juan Pablo Perez-Wert, Sara Martinez-Fdez, Diego Jimenez-Bou, Iciar Ruiz-Gutierrez, Jesus Pena, Ana Pertejo, Enrique Espinosa, Alvaro Pinto
CLINICAL GENITOURINARY CANCER (2022)
Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement
Hossein Taghizadeh, Angela Djanani, Wolfgang Eisterer, Armin Gerger, Birgit Gruenberger, Thomas Gruenberger, Holger Rumpold, Lukas Weiss, Thomas Winder, Ewald Woell, Gerald W. Prager
FRONTIERS IN ONCOLOGY (2023)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C. Dueck, Sophie Frantal, Miguel Martin, Hal J. Burstein, Richard Greil, Peter Fox, Antonio C. Wolff, Arlene Chan, Eric P. Winer, Georg Pfeiler, Kathy D. Miller, Marco Colleoni, Jennifer M. Suga, Gabor Rubovsky, Judith M. Bliss, Ingrid A. Mayer, Christian F. Singer, Zbigniew Nowecki, Olwen Hahn, Jacqui Thomson, Norman Wolmark, Kepa Amillano, Hope S. Rugo, Guenther G. Steger, Blanca Hernando Fernandez de Aranguiz, Tufia C. Haddad, Antonia Perello, Meritxell Bellet, Hannes Fohler, Otto Metzger Filho, Anita Jallitsch-Halper, Kadine Solomon, Celine Schurmans, Kathy P. Theall, Dongrui R. Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L. Mayer
JOURNAL OF CLINICAL ONCOLOGY (2022)
Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes
Julienne E. Bower, Ann H. Partridge, Antonio C. Wolff, Steve W. Cole, Michael R. Irwin, Elissa D. Thorner, Hadine Joffe, Laura Petersen, Catherine M. Crespi, Patricia A. Ganz
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)
Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study
Adith Abraham, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce C. Niland, Antonio C. Wolff, Michael J. Hassett, Sarah Asad, Daniel G. Stover
BREAST (2023)
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A. Carey, Andres Forero-Torres, James N. Ingle, Nancy U. Lin, Rita Nanda, Anna Maria Storniolo, Suzana Tulac, Neesha Venkatesan, Natalie C. Wu, Sudhakar Marla, Scott Campbell, Michael Bates, Christopher B. Umbricht, Antonio C. Wolff, Saraswati Sukumar
CLINICAL CANCER RESEARCH (2023)
Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets
Cesar A. Santa-Maria, Antonio C. Wolff
JOURNAL OF CLINICAL ONCOLOGY (2023)
Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy
Zhengyi Deng, Miranda R. Jones, Mei-Cheng Wang, Antonio C. Wolff, Kala Visvanathan
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)
Evaluating potential overuse of surveillance care in cancer survivors
Jennifer Y. Sheng, Claire F. Snyder, Katherine C. Smith, Jennifer DeSanto, Nancy Mayonado, Susan Rall, Sharon White, Amanda L. Blackford, Fabian M. Johnston, Robert L. Joyner, Joan Mischtschuk, Kimberly S. Peairs, Elissa Thorner, Phuoc T. Tran, Antonio C. Wolff, Youngjee Choi
CANCER MEDICINE (2023)
Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment
Gabrielle B. Rocque, Courtney Andrews, Valerie M. Lawhon, Rachel Frazier, Stacey A. Ingram, Mary Lou Smith, Lynne I. Wagner, Lisa Zubkoff, Nadine Tung, Lauren P. Wallner, Antonio C. Wolff
JCO ONCOLOGY PRACTICE (2023)
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Susana L. Garcia-Recio, Toshinori J. Hinoue, Gregory L. C. Wheeler, Benjamin J. Kelly, Ana C. A. Garrido-Castro, Tomas Pascual, Aguirre A. M. De Cubas, Youli B. Xia, Brooke M. Felsheim, Marni B. McClure, Andrei A. Rajkovic, Ezgi Karaesmen, Markia A. Smith, Cheng E. Fan, Paula I. Gonzalez J. Ericsson, Melinda E. Sanders, Chad J. Creighton, Jay T. Bowen, Kristen Leraas, Robyn T. Burns, Sara Coppens, Amy L. Wheless, Salma S. Rezk, Amy L. K. Garrett, Joel S. Parker, Kelly K. H. Foy, Hui Shen, Ben H. Park, Ian Krop, Carey F. Anders, Julie Gastier-Foster, Mothaffar F. U. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly J. Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael Davis, Jonathan C. Silverstein, Alexander G. Ropelewski, Minetta C. Liu, Susan G. L. Hilsenbeck, Larry Norton, Andrea L. C. Richardson, W. Fraser E. Symmans, Antonio C. A. Wolff, Nancy E. V. Davidson, Lisa A. M. Carey, Adrian V. A. Lee, Justin M. W. Balko, Katherine A. R. Hoadley, Peter W. A. Laird, Elaine R. A. Mardis, Tari A. A. King, Charles M. AURORA US Network, Charles M. Perou
NATURE CANCER (2023)
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials
Laura Pala, Tommaso De Pas, Eleonora Pagan, Isabella Sala, Chiara Catania, Emma Zattarin, Paolo Arnone, Massimo M. Grassi, Marco Colleoni, Antonio C. Wolff, Javier Cortes, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Vincenzo Bagnardi, Fabio Conforti
BREAST (2023)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update
Antonio C. Wolff, Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, Kimberly H. Allison
JOURNAL OF CLINICAL ONCOLOGY (2023)
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
Beverly Moy, Antonio C. Wolff, R. Bryan Rumble, Kimberly H. Allison, Lisa A. Carey
JCO ONCOLOGY PRACTICE (2023)
Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer
Antonio C. Wolff
JOURNAL OF CLINICAL ONCOLOGY (2023)
Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer
Zhengyi Deng, Miranda R. Jones, Antonio C. Wolff, Kala Visvanathan
JNCI CANCER SPECTRUM (2023)
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Pare, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer
LANCET ONCOLOGY (2023)